<SEC-DOCUMENT>0000842023-13-000027.txt : 20131101
<SEC-HEADER>0000842023-13-000027.hdr.sgml : 20131101
<ACCEPTANCE-DATETIME>20131101104805
ACCESSION NUMBER:		0000842023-13-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131031
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131101
DATE AS OF CHANGE:		20131101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		131184727

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8vote2013.txt
<DESCRIPTION>8-K
<TEXT>
                     SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                  FORM 8-K

                                CURRENT REPORT

                 PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

     Date of report (Date of earliest event reported): October 31, 2013

                             TECHNE CORPORATION
          (Exact Name of Registrant as Specified in Charter)

                                  Minnesota
                (State or Other Jurisdiction of Incorporation)

                0-17272                         41-1427402
         (Commission File Number)            (I.R.S. Employer
                                             Identification No.)

                             614 McKinley Place NE
                             Minneapolis, MN 55413
          (Address of Principal Executive Offices)  (Zip Code)

  Registrant's telephone number, including area code:  (612) 379-8854

                                 Not Applicable
       (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions:

__  Written communications pursuant to Rule 425 under the Securities Act
    17 CFR 230.425)

__  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

__  Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

__  Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))






Item 5.07  Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Shareholders (the "Annual Meeting") on
October 31, 2013 at the Company's headquarters in Minneapolis, Minnesota. At
the meeting, 33,541,120 shares were represented in person or by proxy, which
constituted a quorum. The voting results at the Annual Meeting were as set
forth below.

Proposal No. 1 - The shareholders elected each of the nominees to the Board
of Directors:

                               For       Against    Abstain  Broker Non-Vote
                           ----------   ---------   -------  ---------------
Charles R. Kummeth         30,554,045   1,139,513    45,850     1,801,712
Robert V. Baumgartner      26,888,059   4,845,862     5,487     1,801,712
Roger C. Lucas, Ph.D.      30,674,620   1,024,316    40,472     1,801,712
Howard V. O'Connell        26,730,425   4,967,034    41,949     1,801,712
Randolph C. Steer,
  M.D., Ph.D.              26,638,705   5,091,189     9,514     1,801,712
Charles A. Dinarello, M.D. 30,641,558   1,089,814     8,036     1,801,712
Karen A. Holbrook, Ph.D.   30,616,101   1,118,233     5,074     1,801,712
John L. Higgins            26,690,246   5,041,949     7,213     1,801,712
Roeland Nusse, Ph.D.       30,461,632   1,233,166    44,610     1,801,712


Each nominee was elected by a majority voting standard defined in the Amended
and Restated Articles of Incorporation.



Proposal No. 2 - The shareholders voted to set the number of directors at
nine:

        For       Against    Abstain  Broker Non-Vote
    ----------   ---------   -------  ---------------
    33,390,219      64,393    86,508           0



Proposal No. 3 - The shareholders adopted a non-binding resolution approving
the compensation of the Company's named executive officers, as described in
the Company's Proxy Statement for the Annual Meeting:

        For       Against    Abstain  Broker Non-Vote
    ----------   ---------   -------  ---------------
    31,024,888     659,721    54,799     1,801,712


Proposal No. 4 - The shareholders ratified the appointment of KPMG LLP as the
Company's independent registered public accounting firm for the fiscal year
ending June 30, 2012.

        For       Against    Abstain  Broker Non-Vote
    ----------   ---------   -------  ---------------
    32,763,649     721,016    56,455          0



Item 8.01 Other Events

Announcement of Cash Dividend

On October 31, 2013, the Company issued a press release announcing the
payment of a cash dividend.  The full text of the press release is set forth
in Exhibit 99.1 attached hereto and is incorporated by reference as if fully
set forth herein.


Item 9.01	Financial Statements and Exhibits.

	(a)	Financial statements:  None

	(b)	Pro forma financial information:  None

	(c)	Shell Company Transactions:  None

	(d)	Exhibits:

		99.1	Press Release, dated October 31, 2013






                               SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: November 1, 2013

					TECHNE CORPORATION


                                        /s/ Charles R. Kummeth
                                        ------------------------
                                        Charles R. Kummeth
					President and Chief Executive Officer









                  SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C. 20549

                        TECHNE CORPORATION
                       EXHIBIT INDEX TO FORM 8-K


Date of Report:	                                     Commission File No.:
October 31, 2013                                         0-17272

Exhibit No.    ITEM
----------     -------
99.1           Press Release, dated October 31, 2013



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>releasenov13dividend.txt
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 31, 2013
<TEXT>
                  TECHNE CORPORATION DECLARES DIVIDEND


Minneapolis/October 31, 2013/ -- Techne Corporation (NASDAQ:TECH) announced
that its Board of Directors has decided to pay a dividend of $0.31 per share
for the quarter ended September 30, 2013.  The quarterly dividend will be
payable November 25, 2013 to all common shareholders of record on November
12, 2013.  Future cash dividends will be considered by the Board of Directors
on a quarterly basis.




            *  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and clinical
diagnostic controls. These activities are conducted through the Company's two
operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems)
of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of
Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems
has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in
Emeryville, California, Boston Biochem, Inc., located in Cambridge,
Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens,
Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in
Shanghai, China. BiosPacific is a worldwide supplier of biologics to
manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
Boston Biochem is a leading developer and manufacturer of ubiquitin-related
research products.  Bionostics is a leading supplier of control solutions
used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D
Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol,
England and R&D Systems GmbH, a German sales operation. Tocris is a leading
supplier of chemical reagents for non-clinical life science research.

Contact:  Greg Melsen, CFO
          Kathy Backes, Controller
         (612) 379-8854




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
